Table 2.
Analysis Period | Patiromer at 25.2 g/d Averaged across Dosing Regimens | P Valuea |
---|---|---|
4-d Preplanned analysis (days 1–4 versus 19–22) | ||
uK, mg | −1462.1±274.3 | <0.001 |
uNa, mg | −463.2±581.7 | 0.02 |
uMg, mg | −39.1±20.0 | <0.001 |
uCa, mg | 73.5±38.8 | <0.001 |
uP, mg | −143.5±138.1 | <0.01 |
2-d Sensitivity analysis (days 3 and 4 versus 21 and 22) | ||
uK, mg | −1800.2±312.7 | <0.001 |
uNa, mg | −80.5±636.0 | 0.32 |
uMg, mg | −49.5±17.8 | <0.001 |
uCa, mg | 83.3±40.4 | <0.001 |
uP, mg | −109.3±134.5 | <0.02 |
uK, urine potassium; uNa, urine sodium; uMg, urine magnesium; uCa, urine calcium; uP, urine phosphate.
From one–sample t test to determine if the mean change from baseline is significantly different from zero.